Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
The phase II clinical trial (NCT05268016)* was conducted to evaluate the efficacy, safety and tolerability of ME3183 after administered once or twice daily for 16 weeks in patients with moderate-to-severe plaque psoriasis. One-hundred and thirty-two patients were enrolled in the United States and Canada. The primary endpoint was defined as the proportion of subjects achieving 75% improvement (“PASI-75”) in Psoriasis Area Severity Index (PASI) Score at Week 16 from baseline. As a result, significantly greater proportion of PASI-75 achievement were observed in ME3183 treatment groups compared to the placebo group, which met the primary endpoint. In addition, early PASI improvement after administration was observed in ME3183 groups. ME3183 was shown to be safe and well tolerated. Details of the study will be presented at an upcoming medical meeting.
ME3183 is an orally-available and selective PDE4 inhibitor discovered by Meiji Seika Pharma. In non-clinical studies, it showed greater anti-inflammatory effect and approximately 30-fold greater inhibitory effect on TNF-α production than the existing orally-available PDE4 inhibitor for psoriasis. At the same time, the distribution of ME3183 in the brain was sufficiently low.
Meiji strives to provide efficacious and safe treatment for unmet medical needs, such as psoriasis and other autoimmune diseases.
*: Meiji Pharma USA Inc. (Teaneck, NJ, President: Yasushi Miyazawa), a wholly owned subsidiary of Meiji, is in charge of the Phase II clinical trial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808681726/en/
Contact information
Meiji Pharma USA Inc.
Yasushi Miyazawa
President
Telephone: 201-777-7133
E-mail: mpu.contact@meiji-us.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esports World Cup Foundation and Lenovo™ Partner to Power the Next Generation of Esports Champions1.7.2025 16:00:00 EEST | Press release
The Esports World Cup Foundation (EWCF) and Lenovo today announced a partnership to make Lenovo’s Legion brand of gaming devices the Official PC & Gaming Hardware partner of the Esports World Cup 2025 (EWC). Lenovo Legion is the one of the world’s leading gaming ecosystem brands, and will be bring its relentless commitment to innovation and performance to the global stage, empowering EWC athletes to compete at their highest level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626760677/en/ From training rooms to tournament zones, EWC athletes will be equipped with Lenovo Legion Towers, Lenovo Legion laptops, and peripherals – built for elite esports play with advanced thermal systems, high-performance silicon, high refresh-rate displays and low latency keyboards and mice that meet the demands of top-level competition. Key models such as the Legion Tower 7i and Legion Tower 5i will feature across the event’s player infras
Citigroup Announces €1.75 Billion Redemption of 1.250% Fixed Rate/Floating Rate Notes Due 20261.7.2025 15:30:00 EEST | Press release
Citigroup Inc. is announcing the redemption, in whole, constituting €1,750,000,000 of its 1.250% Fixed Rate/Floating Rate Notes due 2026 (the “notes”) (ISIN: XS2167003685). The redemption date for the notes is July 6, 2025 (the “redemption date”). The cash redemption price for the notes payable on the redemption date will equal par plus accrued and unpaid interest, to but excluding, the redemption date and will be paid on July 7, 2025, the next succeeding business day after the redemption date. The redemption announced today is consistent with Citigroup's liability management strategy and reflects its ongoing efforts to enhance the efficiency of its funding and capital structure. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, including without limitation, the economic value, regulatory changes, potential impact on Citigroup's net interest margin and borrowing costs, the overall remaining tenor of Citigroup's debt portfoli
LevelBlue to Acquire Trustwave, Becoming Largest Pure-Play Managed Security Services Provider1.7.2025 15:00:00 EEST | Press release
LevelBlue, a global leader in cloud-based, AI-driven managed security services (MSS), has signed a definitive agreement to acquire Trustwave, a global provider of cybersecurity and managed detection and response (MDR) services from the MC2 Security Fund (MC2), a private equity fund sponsored by The Chertoff Group, an internationally recognized security and growth advisory firm. This strategic acquisition complements LevelBlue’s recent agreement to acquire Aon’s cybersecurity consulting business, formerly known as Stroz Friedberg, and further strengthens the company’s market leadership, uniting two leading Managed Security Service Providers (MSSPs) to deliver unparalleled cybersecurity outcomes through a comprehensive and expanded suite of services designed to stay ahead of the rapidly evolving threat landscape. The acquisition will create the largest pure-play MSSP in the industry. The acquisition will integrate LevelBlue’s extensive expertise in strategic risk management and cybersecu
Vertex Announces European Commission Approval of ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis1.7.2025 14:34:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further improvement in CFTR protein function versus KAFTRIO,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With this approval, we are one step closer to our ultimate goal of restoring normal levels of CFTR function in people living with CF.” In two head-to-head pivotal clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor on ppFEV1 and superior at reducing sweat chloride, demonstrating greater improvem
LTIMindtree Launches GCC-as-a-Service1.7.2025 12:30:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company today introduced its GCC-as-a-Service. The services cater to organizations that may want to set up GCCs, scale their existing ones to optimize costs and create added value. The catalogue covers a spectrum of Build, Operate, Transform and Transfer services, offering clients the option to pick and choose what they require. GCC-as-a-Service commercials are designed on a per-seat or per service basis to ensure cost optimization and value realization. LTIMindtree’s Talent Solutions, part of our Build Services enables clients efficiently onboard business-ready talent from day one through its in-house AI-powered talent acquisition ecosystem. As a part of Transform Services, the Company provides industry specific offerings; technological solutions and frameworks that lead to acceleration of value realization. Clients will be able to leverage its BlueVerse Agentic AI Ecosystem with industry and fu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom